This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Psoriasis Vulgaris
and you are
between 18 and 70
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is an exploratory, single-centre, investigator blinded, randomized, controlled, intra-individual study, involving subjects with psoriasis vulgaris. The objective is to evaluate, in a modified Dumas-Scholtz psoriasis mini-zone test, the safety and efficacy of CD10367 solution at 1% and 3% after a 3-week treatment period of once daily application.

Provided treatments

  • Drug: CD10367 3% Solution - Non-desquamated zone
  • Drug: CD10367 1% Solution - Non-desquamated zone
  • Drug: CD10367 solution placebo - Non-desquamated zone
  • Drug: Betneval ointment - Non-desquamated zone
  • Drug: CD10367 3% Solution - Desquamated zone
  • Drug: CD10367 solution placebo - Desquamated zone

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03025282. The sponsor of the trial is Galderma R&D and it is looking for 24 volunteers for the current phase.
Official trial title:
Exploratory Study to Evaluate the Safety and Efficacy of CD10367 in Subjects With Psoriasis